Incidences of overall and site specific cancers in TNFα inhibitor treated patients with rheumatoid arthritis and other arthritides - a follow-up study from the DANBIO Registry

Lene Dreyer; Lene Mellemkjær; Anne Rødgaard Andersen; Philip Bennett; Uta Engling Poulsen; Torkell Juulsgaard Ellingsen; Torben Høiland Hansen; Dorte Vendelbo Jensen; Louise Linde; Hanne Merete Lindegaard; Anne Gitte Rasmussen Loft; Henrik Nordin; Emina Omerovic; Claus Rasmussen; Annette Schlemmer; Ulrik Tarp; Merete Lund Hetland

doi:10.1136/annrheumdis-2012-201969

Incidences of overall and site specific cancers in TNFα inhibitor treated patients with rheumatoid arthritis and other arthritides - a follow-up study from the DANBIO Registry

Lene Dreyer, Lene Mellemkjær, Anne Rødgaard Andersen, Philip Bennett, Uta Engling Poulsen, Torkell Juulsgaard Ellingsen, Torben Høiland Hansen, Dorte Vendelbo Jensen, Louise Linde, Hanne Merete Lindegaard, Anne Gitte Rasmussen Loft, Henrik Nordin, Emina Omerovic, Claus Rasmussen, Annette Schlemmer, Ulrik Tarp, Merete Lund Hetland

Department of Clinical Medicine

112 Citations (Scopus)

Abstract

Objectives: To investigate the incidence of cancer in arthritis patients treated with or without TNFα inhibitors (TNF-I). Methods: Arthritis patients from the DANBIO database were followed-up for cancer in the Danish Cancer Registry during 2000-2008. Results: Hazard ratio for cancer overall was 1.02 (95% confidence interval (CI) 0.80-1.30) in 3347 TNF-I-treated RA patients compared to non-treated. Excess among TNF-I-treated was found for colon cancer (HR 3.52 (95% CI 1.11-11.15), whereas 6 and 0 ovarian cancer cases were observed in treated and non-treated patients, respectively. Compared to the general population, TNF-Itreated RA patients had increased risk for cancer overall, cancer in lymphatic-haematopoietic tissue and non-melanoma skin cancer, while non-RA patients had no increase in overall cancer risk. Conclusions: Our results suggest that TNF-I therapy in routine care is not associated with an overall excess of cancer in arthritis patients, but observed increased risks of colon and ovarian cancer need further investigation.

Original language	English
Journal	Annals of the Rheumatic Diseases
Volume	72
Issue number	1
Pages (from-to)	79-82
Number of pages	4
ISSN	0003-4967
DOIs	https://doi.org/10.1136/annrheumdis-2012-201969
Publication status	Published - Jan 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1136/annrheumdis-2012-201969

Cite this

Dreyer, L., Mellemkjær, L., Andersen, A. R., Bennett, P., Poulsen, U. E., Juulsgaard Ellingsen, T., Hansen, T. H., Jensen, D. V., Linde, L., Lindegaard, H. M., Loft, A. G. R., Nordin, H., Omerovic, E., Rasmussen, C., Schlemmer, A., Tarp, U., & Hetland, M. L. (2013). Incidences of overall and site specific cancers in TNFα inhibitor treated patients with rheumatoid arthritis and other arthritides - a follow-up study from the DANBIO Registry. Annals of the Rheumatic Diseases, 72(1), 79-82. https://doi.org/10.1136/annrheumdis-2012-201969

Incidences of overall and site specific cancers in TNFα inhibitor treated patients with rheumatoid arthritis and other arthritides - a follow-up study from the DANBIO Registry. / Dreyer, Lene; Mellemkjær, Lene; Andersen, Anne Rødgaard et al.

In: Annals of the Rheumatic Diseases, Vol. 72, No. 1, 01.2013, p. 79-82.

Research output: Contribution to journal › Journal article › Research › peer-review

Dreyer, L, Mellemkjær, L, Andersen, AR, Bennett, P, Poulsen, UE, Juulsgaard Ellingsen, T, Hansen, TH, Jensen, DV, Linde, L, Lindegaard, HM, Loft, AGR, Nordin, H, Omerovic, E, Rasmussen, C, Schlemmer, A, Tarp, U & Hetland, ML 2013, 'Incidences of overall and site specific cancers in TNFα inhibitor treated patients with rheumatoid arthritis and other arthritides - a follow-up study from the DANBIO Registry', Annals of the Rheumatic Diseases, vol. 72, no. 1, pp. 79-82. https://doi.org/10.1136/annrheumdis-2012-201969

@article{1cc83a8a424845808b3688a381929823,

title = "Incidences of overall and site specific cancers in TNFα inhibitor treated patients with rheumatoid arthritis and other arthritides - a follow-up study from the DANBIO Registry",

abstract = "Objectives: To investigate the incidence of cancer in arthritis patients treated with or without TNFα inhibitors (TNF-I). Methods: Arthritis patients from the DANBIO database were followed-up for cancer in the Danish Cancer Registry during 2000-2008. Results: Hazard ratio for cancer overall was 1.02 (95% confidence interval (CI) 0.80-1.30) in 3347 TNF-I-treated RA patients compared to non-treated. Excess among TNF-I-treated was found for colon cancer (HR 3.52 (95% CI 1.11-11.15), whereas 6 and 0 ovarian cancer cases were observed in treated and non-treated patients, respectively. Compared to the general population, TNF-Itreated RA patients had increased risk for cancer overall, cancer in lymphatic-haematopoietic tissue and non-melanoma skin cancer, while non-RA patients had no increase in overall cancer risk. Conclusions: Our results suggest that TNF-I therapy in routine care is not associated with an overall excess of cancer in arthritis patients, but observed increased risks of colon and ovarian cancer need further investigation.",

author = "Lene Dreyer and Lene Mellemkj{\ae}r and Andersen, {Anne R{\o}dgaard} and Philip Bennett and Poulsen, {Uta Engling} and {Juulsgaard Ellingsen}, Torkell and Hansen, {Torben H{\o}iland} and Jensen, {Dorte Vendelbo} and Louise Linde and Lindegaard, {Hanne Merete} and Loft, {Anne Gitte Rasmussen} and Henrik Nordin and Emina Omerovic and Claus Rasmussen and Annette Schlemmer and Ulrik Tarp and Hetland, {Merete Lund}",

year = "2013",

month = jan,

doi = "10.1136/annrheumdis-2012-201969",

language = "English",

volume = "72",

pages = "79--82",

journal = "Annals of the Rheumatic Diseases",

issn = "0003-4967",

publisher = "B M J Group",

number = "1",

}

TY - JOUR

T1 - Incidences of overall and site specific cancers in TNFα inhibitor treated patients with rheumatoid arthritis and other arthritides - a follow-up study from the DANBIO Registry

AU - Dreyer, Lene

AU - Mellemkjær, Lene

AU - Andersen, Anne Rødgaard

AU - Bennett, Philip

AU - Poulsen, Uta Engling

AU - Juulsgaard Ellingsen, Torkell

AU - Hansen, Torben Høiland

AU - Jensen, Dorte Vendelbo

AU - Linde, Louise

AU - Lindegaard, Hanne Merete

AU - Loft, Anne Gitte Rasmussen

AU - Nordin, Henrik

AU - Omerovic, Emina

AU - Rasmussen, Claus

AU - Schlemmer, Annette

AU - Tarp, Ulrik

AU - Hetland, Merete Lund

PY - 2013/1

Y1 - 2013/1

N2 - Objectives: To investigate the incidence of cancer in arthritis patients treated with or without TNFα inhibitors (TNF-I). Methods: Arthritis patients from the DANBIO database were followed-up for cancer in the Danish Cancer Registry during 2000-2008. Results: Hazard ratio for cancer overall was 1.02 (95% confidence interval (CI) 0.80-1.30) in 3347 TNF-I-treated RA patients compared to non-treated. Excess among TNF-I-treated was found for colon cancer (HR 3.52 (95% CI 1.11-11.15), whereas 6 and 0 ovarian cancer cases were observed in treated and non-treated patients, respectively. Compared to the general population, TNF-Itreated RA patients had increased risk for cancer overall, cancer in lymphatic-haematopoietic tissue and non-melanoma skin cancer, while non-RA patients had no increase in overall cancer risk. Conclusions: Our results suggest that TNF-I therapy in routine care is not associated with an overall excess of cancer in arthritis patients, but observed increased risks of colon and ovarian cancer need further investigation.

AB - Objectives: To investigate the incidence of cancer in arthritis patients treated with or without TNFα inhibitors (TNF-I). Methods: Arthritis patients from the DANBIO database were followed-up for cancer in the Danish Cancer Registry during 2000-2008. Results: Hazard ratio for cancer overall was 1.02 (95% confidence interval (CI) 0.80-1.30) in 3347 TNF-I-treated RA patients compared to non-treated. Excess among TNF-I-treated was found for colon cancer (HR 3.52 (95% CI 1.11-11.15), whereas 6 and 0 ovarian cancer cases were observed in treated and non-treated patients, respectively. Compared to the general population, TNF-Itreated RA patients had increased risk for cancer overall, cancer in lymphatic-haematopoietic tissue and non-melanoma skin cancer, while non-RA patients had no increase in overall cancer risk. Conclusions: Our results suggest that TNF-I therapy in routine care is not associated with an overall excess of cancer in arthritis patients, but observed increased risks of colon and ovarian cancer need further investigation.

U2 - 10.1136/annrheumdis-2012-201969

DO - 10.1136/annrheumdis-2012-201969

M3 - Journal article

C2 - 22945500

SN - 0003-4967

VL - 72

SP - 79

EP - 82

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

IS - 1

ER -

Incidences of overall and site specific cancers in TNFα inhibitor treated patients with rheumatoid arthritis and other arthritides - a follow-up study from the DANBIO Registry

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this